Efficacy of fluvoxamine in treatment-refractory depression

Pedro L. Delgado, Lawrence H. Price, Dennis S. Charney, George R. Heninger

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

The efficacy of the potent and selective unicyclic serotonin reuptake inhibitor, fluvoxamine, was evaluated in 38 consecutively admitted depressed patients judged refractory to standard antidepressants using operationalized criteria. Twenty-eight patients completed a single-blind protocol involving ≥2 weeks of placebo and 4-6 weeks of active fluvoxamine. Eight (29%) were judged responders to fluvoxamine alone, eight (29%) responded to lithium augmentation of fluvoxamine and two (7%) responded to fluvoxamine, lithium and perphenazine. These data suggest that selective and potent serotonin reuptake inhibitors may be effective in patients refractory to generally available antidepressant medications.

Original languageEnglish (US)
Pages (from-to)55-60
Number of pages6
JournalJournal of Affective Disorders
Volume15
Issue number1
DOIs
StatePublished - 1988
Externally publishedYes

Fingerprint

Treatment-Resistant Depressive Disorder
Fluvoxamine
Serotonin Uptake Inhibitors
Lithium
Antidepressive Agents
Perphenazine
Therapeutics
Placebos

Keywords

  • Fluvoxamine
  • Lithium
  • Treatment-refractory depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Delgado, P. L., Price, L. H., Charney, D. S., & Heninger, G. R. (1988). Efficacy of fluvoxamine in treatment-refractory depression. Journal of Affective Disorders, 15(1), 55-60. https://doi.org/10.1016/0165-0327(88)90009-2

Efficacy of fluvoxamine in treatment-refractory depression. / Delgado, Pedro L.; Price, Lawrence H.; Charney, Dennis S.; Heninger, George R.

In: Journal of Affective Disorders, Vol. 15, No. 1, 1988, p. 55-60.

Research output: Contribution to journalArticle

Delgado, PL, Price, LH, Charney, DS & Heninger, GR 1988, 'Efficacy of fluvoxamine in treatment-refractory depression', Journal of Affective Disorders, vol. 15, no. 1, pp. 55-60. https://doi.org/10.1016/0165-0327(88)90009-2
Delgado, Pedro L. ; Price, Lawrence H. ; Charney, Dennis S. ; Heninger, George R. / Efficacy of fluvoxamine in treatment-refractory depression. In: Journal of Affective Disorders. 1988 ; Vol. 15, No. 1. pp. 55-60.
@article{a6e4cd7b6a334925ae5d3066c372c11e,
title = "Efficacy of fluvoxamine in treatment-refractory depression",
abstract = "The efficacy of the potent and selective unicyclic serotonin reuptake inhibitor, fluvoxamine, was evaluated in 38 consecutively admitted depressed patients judged refractory to standard antidepressants using operationalized criteria. Twenty-eight patients completed a single-blind protocol involving ≥2 weeks of placebo and 4-6 weeks of active fluvoxamine. Eight (29{\%}) were judged responders to fluvoxamine alone, eight (29{\%}) responded to lithium augmentation of fluvoxamine and two (7{\%}) responded to fluvoxamine, lithium and perphenazine. These data suggest that selective and potent serotonin reuptake inhibitors may be effective in patients refractory to generally available antidepressant medications.",
keywords = "Fluvoxamine, Lithium, Treatment-refractory depression",
author = "Delgado, {Pedro L.} and Price, {Lawrence H.} and Charney, {Dennis S.} and Heninger, {George R.}",
year = "1988",
doi = "10.1016/0165-0327(88)90009-2",
language = "English (US)",
volume = "15",
pages = "55--60",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Efficacy of fluvoxamine in treatment-refractory depression

AU - Delgado, Pedro L.

AU - Price, Lawrence H.

AU - Charney, Dennis S.

AU - Heninger, George R.

PY - 1988

Y1 - 1988

N2 - The efficacy of the potent and selective unicyclic serotonin reuptake inhibitor, fluvoxamine, was evaluated in 38 consecutively admitted depressed patients judged refractory to standard antidepressants using operationalized criteria. Twenty-eight patients completed a single-blind protocol involving ≥2 weeks of placebo and 4-6 weeks of active fluvoxamine. Eight (29%) were judged responders to fluvoxamine alone, eight (29%) responded to lithium augmentation of fluvoxamine and two (7%) responded to fluvoxamine, lithium and perphenazine. These data suggest that selective and potent serotonin reuptake inhibitors may be effective in patients refractory to generally available antidepressant medications.

AB - The efficacy of the potent and selective unicyclic serotonin reuptake inhibitor, fluvoxamine, was evaluated in 38 consecutively admitted depressed patients judged refractory to standard antidepressants using operationalized criteria. Twenty-eight patients completed a single-blind protocol involving ≥2 weeks of placebo and 4-6 weeks of active fluvoxamine. Eight (29%) were judged responders to fluvoxamine alone, eight (29%) responded to lithium augmentation of fluvoxamine and two (7%) responded to fluvoxamine, lithium and perphenazine. These data suggest that selective and potent serotonin reuptake inhibitors may be effective in patients refractory to generally available antidepressant medications.

KW - Fluvoxamine

KW - Lithium

KW - Treatment-refractory depression

UR - http://www.scopus.com/inward/record.url?scp=0023918842&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023918842&partnerID=8YFLogxK

U2 - 10.1016/0165-0327(88)90009-2

DO - 10.1016/0165-0327(88)90009-2

M3 - Article

C2 - 2970493

AN - SCOPUS:0023918842

VL - 15

SP - 55

EP - 60

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 1

ER -